Lupin Limited (NSE: LUPIN) trades at ₹1,980.30 with a market capitalisation of about ₹90,558 crore. Its price-to-book ratio of 3.76 is below the Healthcare sector median of 4.82. Return on equity of 25.27 is above the Healthcare sector median of 12.70. Its P/E ratio of 14.88 is below the Healthcare sector median of 45.24. The share is trading 11.0% below its 200-day moving average (Downtrend).
| Metric | Value |
|---|---|
| Price (₹) | 1,980.30 |
| Market cap (₹ Cr) | 90,558 |
| P/B | 3.76 |
| ROE (%) | 25.3 |
| P/E | 14.9 |
| Distance from 200-DMA (%) | -11.0 |
| Trend | Downtrend |
| Quant rating | Positive |
| Alpha score | 75 / 100 |
Lupin has demonstrated a strong financial turnaround, moving to a net cash positive position and showing healthy cash flow generation. However, the audit report noted limitations in internal financial controls related to accounting software, and the company faces ongoing civil antitrust lawsuits, which are governance-related concerns. Promoter holding is stable with minor changes, and no severe fraud investigations are reported.
Promoter guidance for accelerated growth, particularly in complex generics and India formulations, is genuinely achievable due to a robust product pipeline, strategic capex for complex products, and strong market tailwinds. However, sustained high margins depend on continuously replacing expiring US exclusivities.
Open interactive view → Financials on Screener ↗